Performance status-1 - Slightly symptomatic Posts on Medivizor
Navigation Menu

Performance status-1 – Slightly symptomatic Posts on Medivizor

Looking patients with metastatic triple negative breast cancer to trial a radiation treatment

Posted by on Jun 29, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effectiveness of stereotactic body radiotherapy (SBRT) in patients with metastatic cancer. The main outcome will be progression-free survival (PFS; survival without the cancer getting worse).  This trial is recruiting in multiple locations in New York and New Jersey, US. The details...

Read More

Searching for patients with previously treated non-small cell lung cancer to trial an immunotherapy combination

Posted by on Jun 29, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if treating recurrent non-small cell lung cancer with ramucirumab (Cyramza) and pembrolizumab (Keytruda) works better than standard care practices. The main outcome that will be measured is the overall survival rates.  This study will take place in the United States. The details There are a...

Read More

Search for patients with relapsed or unresponsive small cell lung cancer to try a treatment combination

Posted by on Jun 29, 2019 in Lung cancer | 0 comments

In a nutshell This study wants to find out how well talazoparib (Talzenna) and temozolomide (Temodal) work for treating patients with small cell lung cancer that has come back after or was unresponsive to initial chemotherapy. The main outcome that will be measured is how long the patients go before the cancer grows. The study is...

Read More

Searching for patients with advanced triple negative breast cancer to trial a new treatment into the tumor

Posted by on Jun 28, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 study will investigate Tavokinogene Telseplasmid Electroporation (TTE) in combination with pembrolizumab (Keytruda) in advanced or not suitable for surgery triple-negative breast cancer (TNBC). The main outcome will be the objective response rate (ORR). This trial is recruiting in the United States and...

Read More

Searching for patients with non-small cell lung cancer to test this new treatment combination

Posted by on Jun 24, 2019 in Lung cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with non-small cell lung cancer (NSCLC). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or disappearance).  The details A treatment option for...

Read More

Searching for patients with previously treated colorectal cancer to test this new immunotherapy option

Posted by on Jun 14, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1b trial is examining the effectiveness and safety of cibisatamab in combination with atezolizumab (Tecentriq) after treatment with obinutuzumab (Gazyva) in patients with previously treated metastatic colorectal carcinoma (mCRC).  The main outcomes to be measured will be side effects and...

Read More

Looking patients with advanced cancer to test a new immunotherapy combination

Posted by on May 31, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...

Read More

Searching for patients with locally advanced non-small cell lung cancer to test a chemoradiotherapy regimen

Posted by on May 28, 2019 in Lung cancer | 0 comments

In a nutshell This trial is examining the effectiveness and safety of standard chemoradiation vs a PET base chemoradiation combination in patients with non-small cell lung carcinoma (NSCLC). The main outcomes to be measured will be side effects and survival without cancer growing or spreading. The details A treatment option for...

Read More

Searching for patients with advanced triple negative breast cancer to test this new treatment option

Posted by on May 26, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness and safety of KY1044 alone and in combination with atezolizumab (Tecentriq) for patients with advanced cancers who are not suitable for any other treatment or have failed all other treatment options. The main outcomes to be measured will be the occurrence and severity of side effects and...

Read More